Results 121 to 130 of about 18,447 (220)
Back Again to the Future: A New Era for Cerebroprotection
Cerebroprotection is a fresh framework for designing neurological therapy that targets glia and vascular cells, in addition to neurons. In the future, successful cerebroprotection will involve targeting all elements of the neurovascular unit. Preclinical trials must include functional outcomes, as well as lesion morphometry.
Patrick Lyden
wiley +1 more source
Status Epilepsy Syndromes Made Easy: Pediatric Perspectives. [PDF]
Hon KLE +3 more
europepmc +1 more source
Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies [PDF]
Thio, Liu Lin, Weisenberg, Judith
core +1 more source
Objectives Multiple sclerosis (MS) onset risk factors include Epstein–Barr virus (EBV) indices (including host response), lower serum 25‐vitamin D (25(OH)D) levels, low sun exposure, and HLA‐DRB1*1501. The underlying molecular mechanisms are unclear. Here, we examined mediation through differential DNA methylation (DNAm) to better understand possible ...
Steve Simpson‐Yap +37 more
wiley +1 more source
Ictal MEG-EEG Study to Localize the Onset of Generalized Seizures: To See Beyond What Meets the Eye. [PDF]
Gumenyuk V +7 more
europepmc +1 more source
Objective Biomarkers with clear contexts of use are important tools for amyotrophic lateral sclerosis (ALS) therapy development. Understanding their longitudinal trajectory in the untreated state is key to their use as potential markers of pharmacodynamic response.
Oleksandr Dergai +16 more
wiley +1 more source
The potential of laminar functional MRI in refining the understanding of epilepsy in humans. [PDF]
Aitken F +3 more
europepmc +1 more source
An overview of epilepsy with a focus on the effects and implications of the condition for children and their families [PDF]
Featherstone, VA
core +1 more source
Objective The growing demand for personalized treatment in multiple sclerosis (MS) highlights the need for more precise biomarkers that can outperform magnetic resonance imaging and clinical assessment in patient stratification. Advances in multiplex proteomic technologies suggest that cerebrospinal fluid (CSF) analysis at MS onset may not only improve
Laura Ghezzi +10 more
wiley +1 more source

